TY - JOUR
T1 - Low incidence of restenosis after successful balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension
AU - Tabuchi, Isao
AU - Ogawa, Aiko
AU - Shigetoshi, Masataka
AU - Shimokawahara, Hiroto
AU - Ito, Hiroshi
AU - Matsubara, Hiromi
N1 - Funding Information:
Dr. Ogawa received lecture fees from Nippon Shinyaku, Co., Ltd.; Pfizer Japan, Inc.; and Actelion Japan, Ltd. Dr. Shimokawahara received lecture fees from Daiichi Sankyo Co., Ltd.; Bayer Yakuhin, Ltd.; Nippon Shinyaku, Co., Ltd.; Actelion Pharmaceuticals Japan, Ltd.; and received research funding from Bayer Yakuhin, Ltd. Dr. Matsubara received lecture fees from Nippon Shinyaku, Co., Ltd.; Bayer AG; Pfizer Japan, Inc.; Actelion Pharmaceuticals Ltd.; GlaxoSmithKline plc.; United Therapeutics Corp.; AOP Orphan Pharmaceuticals AG.; Grupo Ferrer Internacional SA.; and Kaneka Medix Co. Dr. Ogawa and Dr. Matsubara are involved in collaborative research with Nippon Shinyaku, Co., Ltd. Other authors report no conflicts.
Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Japanese Association of Cardiovascular Intervention and Therapeutics.
PY - 2022
Y1 - 2022
N2 - Balloon pulmonary angioplasty (BPA) is now a treatment option for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, the incidence of restenosis and long-term changes in vessel diameters in pulmonary arteries after BPA are unknown. The present study investigated the incidence of restenosis by measuring changes in vessel diameter after BPA. We reviewed 58 patients (168 lesions) with CTEPH who underwent single dilation for the target lesion (type A/B/C lesions) during BPA procedure followed by selective pulmonary angiography more than 6 months after the final BPA procedure. The outcomes of BPA were assessed in terms of pulmonary artery diameters. In a median follow-up of 1.9 (1.2–2.7) years, restenosis occurred in only one case with a type C lesion after BPA (0.6%). In type A/B lesions, the minimal lumen diameter was significantly enlarged at follow-up after BPA [3.48 (2.59–4.34) to 4.22 (3.31–4.90) mm]. In type C lesions, the minimal lumen diameter was unchanged at follow-up after BPA [3.15 (1.96–3.64) to 3.28 (2.38–4.61) mm]. The present results revealed that restenosis after BPA rarely occurs in type A/B/C lesions. Minimal lumen diameters for type A/B lesions continually increased and those for type C lesions did not decrease. Stent implantation in type A/B/C lesions would be unnecessary after BPA.
AB - Balloon pulmonary angioplasty (BPA) is now a treatment option for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, the incidence of restenosis and long-term changes in vessel diameters in pulmonary arteries after BPA are unknown. The present study investigated the incidence of restenosis by measuring changes in vessel diameter after BPA. We reviewed 58 patients (168 lesions) with CTEPH who underwent single dilation for the target lesion (type A/B/C lesions) during BPA procedure followed by selective pulmonary angiography more than 6 months after the final BPA procedure. The outcomes of BPA were assessed in terms of pulmonary artery diameters. In a median follow-up of 1.9 (1.2–2.7) years, restenosis occurred in only one case with a type C lesion after BPA (0.6%). In type A/B lesions, the minimal lumen diameter was significantly enlarged at follow-up after BPA [3.48 (2.59–4.34) to 4.22 (3.31–4.90) mm]. In type C lesions, the minimal lumen diameter was unchanged at follow-up after BPA [3.15 (1.96–3.64) to 3.28 (2.38–4.61) mm]. The present results revealed that restenosis after BPA rarely occurs in type A/B/C lesions. Minimal lumen diameters for type A/B lesions continually increased and those for type C lesions did not decrease. Stent implantation in type A/B/C lesions would be unnecessary after BPA.
KW - Angiography
KW - Hypertension
KW - Pulmonary
KW - Quantitative vascular analysis
UR - http://www.scopus.com/inward/record.url?scp=85132321346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132321346&partnerID=8YFLogxK
U2 - 10.1007/s12928-022-00866-y
DO - 10.1007/s12928-022-00866-y
M3 - Article
AN - SCOPUS:85132321346
JO - Cardiovascular Intervention and Therapeutics
JF - Cardiovascular Intervention and Therapeutics
SN - 1868-4300
ER -